NASDAQ:TMDX

TransMedics Group Competitors

$29.12
+0.18 (+0.62 %)
(As of 04/14/2021 03:59 PM ET)
Add
Compare
Today's Range
$28.94
Now: $29.12
$30.41
50-Day Range
$28.61
MA: $37.76
$47.82
52-Week Range
$11.51
Now: $29.12
$49.50
Volume15,592 shs
Average Volume834,047 shs
Market Capitalization$797.01 million
P/E RatioN/A
Dividend YieldN/A
Beta2.16

Competitors

TransMedics Group (NASDAQ:TMDX) Vs. INMD, OM, BLFS, NTUS, AXGN, and VRAY

Should you be buying TMDX stock or one of its competitors? Companies in the industry of "electromedical equipment" are considered alternatives and competitors to TransMedics Group, including InMode (INMD), Outset Medical (OM), BioLife Solutions (BLFS), Natus Medical (NTUS), AxoGen (AXGN), and ViewRay (VRAY).

TransMedics Group (NASDAQ:TMDX) and InMode (NASDAQ:INMD) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

Institutional and Insider Ownership

76.7% of TransMedics Group shares are held by institutional investors. Comparatively, 35.7% of InMode shares are held by institutional investors. 13.1% of TransMedics Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Volatility and Risk

TransMedics Group has a beta of 2.16, indicating that its stock price is 116% more volatile than the S&P 500. Comparatively, InMode has a beta of 1.95, indicating that its stock price is 95% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for TransMedics Group and InMode, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
TransMedics Group02302.60
InMode00403.00

TransMedics Group presently has a consensus price target of $44.20, suggesting a potential upside of 52.73%. InMode has a consensus price target of $71.50, suggesting a potential downside of 14.17%. Given TransMedics Group's higher possible upside, analysts clearly believe TransMedics Group is more favorable than InMode.

Profitability

This table compares TransMedics Group and InMode's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TransMedics Group-131.35%-38.95%-24.10%
InMode32.57%28.56%24.14%

Earnings & Valuation

This table compares TransMedics Group and InMode's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TransMedics Group$23.60 million33.56$-33,550,000.00($2.36)-12.26
InMode$156.36 million17.02$61.15 million$1.6052.03

InMode has higher revenue and earnings than TransMedics Group. TransMedics Group is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Summary

InMode beats TransMedics Group on 9 of the 14 factors compared between the two stocks.

TransMedics Group (NASDAQ:TMDX) and Outset Medical (NASDAQ:OM) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

Profitability

This table compares TransMedics Group and Outset Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TransMedics Group-131.35%-38.95%-24.10%
Outset MedicalN/AN/AN/A

Earnings & Valuation

This table compares TransMedics Group and Outset Medical's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TransMedics Group$23.60 million33.56$-33,550,000.00($2.36)-12.26
Outset MedicalN/AN/AN/AN/AN/A

Outset Medical has lower revenue, but higher earnings than TransMedics Group.

Institutional and Insider Ownership

76.7% of TransMedics Group shares are held by institutional investors. Comparatively, 84.6% of Outset Medical shares are held by institutional investors. 13.1% of TransMedics Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and target prices for TransMedics Group and Outset Medical, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
TransMedics Group02302.60
Outset Medical03402.57

TransMedics Group presently has a consensus price target of $44.20, suggesting a potential upside of 52.73%. Outset Medical has a consensus price target of $56.50, suggesting a potential upside of 3.76%. Given TransMedics Group's stronger consensus rating and higher possible upside, analysts clearly believe TransMedics Group is more favorable than Outset Medical.

Summary

Outset Medical beats TransMedics Group on 5 of the 9 factors compared between the two stocks.

TransMedics Group (NASDAQ:TMDX) and BioLife Solutions (NASDAQ:BLFS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation and earnings.

Analyst Ratings

This is a breakdown of current recommendations and price targets for TransMedics Group and BioLife Solutions, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
TransMedics Group02302.60
BioLife Solutions01902.90

TransMedics Group currently has a consensus target price of $44.20, indicating a potential upside of 52.73%. BioLife Solutions has a consensus target price of $46.6667, indicating a potential upside of 38.03%. Given TransMedics Group's higher probable upside, research analysts plainly believe TransMedics Group is more favorable than BioLife Solutions.

Institutional & Insider Ownership

76.7% of TransMedics Group shares are owned by institutional investors. Comparatively, 67.7% of BioLife Solutions shares are owned by institutional investors. 13.1% of TransMedics Group shares are owned by insiders. Comparatively, 22.3% of BioLife Solutions shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

TransMedics Group has a beta of 2.16, indicating that its share price is 116% more volatile than the S&P 500. Comparatively, BioLife Solutions has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500.

Profitability

This table compares TransMedics Group and BioLife Solutions' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TransMedics Group-131.35%-38.95%-24.10%
BioLife Solutions12.67%0.53%0.43%

Valuation and Earnings

This table compares TransMedics Group and BioLife Solutions' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TransMedics Group$23.60 million33.56$-33,550,000.00($2.36)-12.26
BioLife Solutions$27.37 million41.26$-1,660,000.00$0.08422.63

BioLife Solutions has higher revenue and earnings than TransMedics Group. TransMedics Group is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Summary

BioLife Solutions beats TransMedics Group on 10 of the 14 factors compared between the two stocks.

Natus Medical (NASDAQ:NTUS) and TransMedics Group (NASDAQ:TMDX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability and earnings.

Earnings and Valuation

This table compares Natus Medical and TransMedics Group's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Natus Medical$495.52 million1.94$-15,670,000.00$1.2422.84
TransMedics Group$23.60 million33.56$-33,550,000.00($2.36)-12.26

Natus Medical has higher revenue and earnings than TransMedics Group. TransMedics Group is trading at a lower price-to-earnings ratio than Natus Medical, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for Natus Medical and TransMedics Group, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Natus Medical01002.00
TransMedics Group02302.60

TransMedics Group has a consensus price target of $44.20, indicating a potential upside of 52.73%. Given TransMedics Group's stronger consensus rating and higher probable upside, analysts clearly believe TransMedics Group is more favorable than Natus Medical.

Volatility and Risk

Natus Medical has a beta of 0.72, indicating that its share price is 28% less volatile than the S&P 500. Comparatively, TransMedics Group has a beta of 2.16, indicating that its share price is 116% more volatile than the S&P 500.

Profitability

This table compares Natus Medical and TransMedics Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Natus Medical-4.33%3.87%2.50%
TransMedics Group-131.35%-38.95%-24.10%

Institutional & Insider Ownership

89.7% of Natus Medical shares are owned by institutional investors. Comparatively, 76.7% of TransMedics Group shares are owned by institutional investors. 1.5% of Natus Medical shares are owned by company insiders. Comparatively, 13.1% of TransMedics Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

TransMedics Group (NASDAQ:TMDX) and AxoGen (NASDAQ:AXGN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, profitability, earnings, analyst recommendations and risk.

Analyst Ratings

This is a breakdown of current recommendations for TransMedics Group and AxoGen, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
TransMedics Group02302.60
AxoGen02302.60

TransMedics Group presently has a consensus target price of $44.20, indicating a potential upside of 52.73%. AxoGen has a consensus target price of $23.75, indicating a potential upside of 21.48%. Given TransMedics Group's higher probable upside, analysts plainly believe TransMedics Group is more favorable than AxoGen.

Institutional & Insider Ownership

76.7% of TransMedics Group shares are held by institutional investors. Comparatively, 78.4% of AxoGen shares are held by institutional investors. 13.1% of TransMedics Group shares are held by insiders. Comparatively, 6.9% of AxoGen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares TransMedics Group and AxoGen's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TransMedics Group$23.60 million33.56$-33,550,000.00($2.36)-12.26
AxoGen$106.71 million7.47$-29,140,000.00($0.68)-28.75

AxoGen has higher revenue and earnings than TransMedics Group. AxoGen is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

TransMedics Group has a beta of 2.16, suggesting that its share price is 116% more volatile than the S&P 500. Comparatively, AxoGen has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500.

Profitability

This table compares TransMedics Group and AxoGen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TransMedics Group-131.35%-38.95%-24.10%
AxoGen-22.98%-19.83%-14.88%

Summary

AxoGen beats TransMedics Group on 7 of the 12 factors compared between the two stocks.

TransMedics Group (NASDAQ:TMDX) and ViewRay (NASDAQ:VRAY) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

Insider & Institutional Ownership

76.7% of TransMedics Group shares are held by institutional investors. Comparatively, 83.0% of ViewRay shares are held by institutional investors. 13.1% of TransMedics Group shares are held by insiders. Comparatively, 15.5% of ViewRay shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and price targets for TransMedics Group and ViewRay, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
TransMedics Group02302.60
ViewRay11502.57

TransMedics Group presently has a consensus price target of $44.20, suggesting a potential upside of 52.73%. ViewRay has a consensus price target of $4.50, suggesting a potential upside of 2.97%. Given TransMedics Group's stronger consensus rating and higher probable upside, research analysts clearly believe TransMedics Group is more favorable than ViewRay.

Earnings & Valuation

This table compares TransMedics Group and ViewRay's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TransMedics Group$23.60 million33.56$-33,550,000.00($2.36)-12.26
ViewRay$87.78 million8.01$-120,200,000.00($1.18)-3.70

TransMedics Group has higher earnings, but lower revenue than ViewRay. TransMedics Group is trading at a lower price-to-earnings ratio than ViewRay, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

TransMedics Group has a beta of 2.16, meaning that its share price is 116% more volatile than the S&P 500. Comparatively, ViewRay has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500.

Profitability

This table compares TransMedics Group and ViewRay's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TransMedics Group-131.35%-38.95%-24.10%
ViewRay-166.74%-63.41%-36.34%

Summary

TransMedics Group beats ViewRay on 8 of the 14 factors compared between the two stocks.


TransMedics Group Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
InMode logo
INMD
InMode
1.5$83.25flat$2.68 billion$156.36 million59.89Analyst Downgrade
Outset Medical logo
OM
Outset Medical
1.0$54.45flat$2.34 billionN/A0.00Analyst Upgrade
BioLife Solutions logo
BLFS
BioLife Solutions
2.1$33.81flat$1.16 billion$27.37 million-46.31Insider Selling
Increase in Short Interest
NTUS
Natus Medical
1.1$28.32flat$926.45 million$495.52 million-51.49
AxoGen logo
AXGN
AxoGen
1.5$19.55flat$801.17 million$106.71 million-31.03News Coverage
ViewRay logo
VRAY
ViewRay
1.3$4.37flat$691.44 million$87.78 million-4.91
Cutera logo
CUTR
Cutera
1.3$31.04flat$556.07 million$181.71 million-17.15Gap Down
Zynex logo
ZYXI
Zynex
1.8$15.28flat$523.87 million$45.47 million46.30
Edap Tms logo
EDAP
Edap Tms
1.3$9.21flat$267.82 million$50.23 million-153.50Increase in Short Interest
Second Sight Medical Products logo
EYES
Second Sight Medical Products
0.8$8.06flat$195.07 million$3.38 million-4.22Decrease in Short Interest
BioSig Technologies logo
BSGM
BioSig Technologies
0.5$4.29flat$137.33 millionN/A0.00News Coverage
FONR
FONAR
1.1$18.17flat$117.78 million$85.69 million17.14
IRIDEX logo
IRIX
IRIDEX
0.9$7.40flat$113.61 million$43.45 million-13.45Gap Down
ENDRA Life Sciences logo
NDRA
ENDRA Life Sciences
0.6$2.24flat$98.18 million$10,000.00-1.22Analyst Upgrade
Increase in Short Interest
Soleno Therapeutics logo
SLNO
Soleno Therapeutics
1.9$1.23flat$94.87 millionN/A-1.62Increase in Short Interest
electroCore logo
ECOR
electroCore
1.4$1.80flat$89.20 million$2.39 million-2.28Decrease in Short Interest
Gap Up
Helius Medical Technologies logo
HSDT
Helius Medical Technologies
1.5$16.78flat$40.28 million$1.50 million-0.96Increase in Short Interest
CHF Solutions logo
CHFS
CHF Solutions
1.7$5.28flat$31.63 million$5.51 million-0.11Increase in Short Interest
Gap Down
Viveve Medical logo
VIVE
Viveve Medical
0.9$3.01flat$31.03 million$6.57 million-0.01
STRR
Star Equity
0.1$3.22flat$16.24 million$114.18 million-1.03
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.